{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:46:01Z","timestamp":1781977561345,"version":"3.54.5"},"reference-count":52,"publisher":"Radiation Research Society","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bioone.org\/page\/resources\/researchers\/rights_and_permissions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiation Research"],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1667\/rr15121.1","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T14:27:30Z","timestamp":1538576850000},"page":"350","source":"Crossref","is-referenced-by-count":24,"title":["Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15\u201318 October 2017; Cancun, Mexico"],"prefix":"10.1667","volume":"190","author":[{"given":"Kelly C.","family":"Falls","sequence":"first","affiliation":[{"name":"Free Radical and Radiation Biology Program, Department of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky A.","family":"Sharma","sequence":"additional","affiliation":[{"name":"NHR University College of London Hospitals Biomedical Research Center, UCL Cancer Institute, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaacov R.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Radiation Oncology, Department of Radiation Oncology, Sheba Medical Center affiliated with Tel Aviv University, Tel HaShomer 5265601, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Amos","sequence":"additional","affiliation":[{"name":"Proton and Advanced Radiotherapy Group, Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil J.","family":"Advani","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California, San Diego, Moores Cancer Center, La Jolla, California 92093"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor M.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Division of Cancer Treatment and Diagnosis, Radiation Research Program, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhadrasain","family":"Vikram","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Division of Cancer Treatment and Diagnosis, Radiation Research Program, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Norman","family":"Coleman","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Division of Cancer Treatment and Diagnosis, Radiation Research Program, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pataje G.","family":"Prasanna","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Division of Cancer Treatment and Diagnosis, Radiation Research Program, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1243","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"M, Baumann, M, Krause, J, Overgaard, et al. \"Nat Rev Cancer.\" 16, \"Radiation oncology in the era of precision medicine\" 234 (2016)","DOI":"10.1038\/nrc.2016.18"},{"key":"2","doi-asserted-by":"crossref","unstructured":"YR, Lawrence, B, Vikram, JJ, Dignam, et al. \"J Natl Cancer Inst.\" 105, \"NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers\" 11 (2013)","DOI":"10.1093\/jnci\/djs472"},{"key":"3","doi-asserted-by":"crossref","unstructured":"OU, Ataman, SJ, Sambrook, C, Wilks, et al. \"Int J Radiat Oncol Biol Phys.\" 84, \"The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective\" e447 (2012)","DOI":"10.1016\/j.ijrobp.2012.05.019"},{"key":"4","doi-asserted-by":"crossref","unstructured":"U, Ringborg, D, Bergqvist, B, Brorsson, et al. \"Acta Oncol.\" 42, \"The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001\u2013summary and conclusions\" 357 (2003)","DOI":"10.1080\/02841860310010826"},{"key":"5","doi-asserted-by":"crossref","unstructured":"RA, Sharma, R, Plummer, JK, Stock, et al. \"Nat Rev Clin Oncol.\" 13, \"Clinical development of new drug-radiotherapy combinations\" 627 (2016)","DOI":"10.1038\/nrclinonc.2016.79"},{"key":"6","doi-asserted-by":"crossref","unstructured":"JA, Bonner, PM, Harari, J, Giralt, et al. \"N Engl J Med.\" 354, \"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck\" 567 (2006)","DOI":"10.1056\/NEJMoa053422"},{"key":"7","unstructured":"JA, Bonner, KP, Raisch, HQ, Trummell, et al. \"J Clin Oncol.\" 18, \"Enhanced apoptosis with combination C225\/radiation treatment serves as the impetus for clinical investigation in head and neck cancers\" 47s (2000)"},{"key":"8","doi-asserted-by":"crossref","unstructured":"R, Pirker, JR, Pereira, A, Szczesna, et al. \"Lancet.\" 373, \"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial\" 1525 (2009)","DOI":"10.1016\/S0140-6736(09)60569-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"MM, Ahmed, CN, Coleman, M, Mendonca, et al. \"Cancer Res.\" 78, \"Workshop Report for cancer research: Defining the shades of Gy: Utilizing the biological consequences of radiotherapy in the development of new treatment approaches-meeting viewpoint\" 2166 (2018)","DOI":"10.1158\/0008-5472.CAN-17-3760"},{"key":"10","doi-asserted-by":"crossref","unstructured":"CN, Coleman, GS, Higgins, JM, Brown, et al. \"Clin Cancer Res.\" 22, \"Improving the predictive value of preclinical studies in support of radiotherapy clinical trials\" 3138 (2016)","DOI":"10.1158\/1078-0432.CCR-16-0069"},{"key":"11","doi-asserted-by":"crossref","unstructured":"HB, Stone, EJ, Bernhard, CN, Coleman, et al. \"Transl Oncol.\" 9, \"Preclinical data on efficacy of 10 drug-radiation combinations: evaluations, concerns, and recommendations\" 46 (2016)","DOI":"10.1016\/j.tranon.2016.01.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"PG, Prasanna, D, Narayanan, K, Hallett, et al. \"Radiat Res.\" 184, \"Radioprotectors and radiomitigators for improving radiation therapy: the Small Business Innovation Research (SBIR) gateway for accelerating clinical translation\" 235 (2015)","DOI":"10.1667\/RR14186.1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"CN, Coleman, PGS, Prasanna, , EJ, Bernhard, et al. \"Int J Radiat Oncol Biol Phys.\" 101, \"Accurate, precision radiation medicine: A meta-strategy for impacting cancer care, global health, nuclear policy, and mitigating radiation injury from necessary medical use, space exploration and potential terrorism\" 250 (2018)","DOI":"10.1016\/j.ijrobp.2018.02.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"KJ, Harrington, LJ, Billingham, TB, Brunner, et al. \"Br J Cancer.\" 105, \"Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers\" 628 (2011)","DOI":"10.1038\/bjc.2011.240"},{"key":"15","unstructured":"et al. \"NCRI Radiotherapy-Drug Combinations Consortium (RaDCom).\" , (2015)"},{"key":"16","doi-asserted-by":"crossref","unstructured":"MA, Metwally, KD, Frederiksen, J. Overgaard, \"Acta Oncol.\" 53, \"Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC)\" 654 (2014)","DOI":"10.3109\/0284186X.2013.864050"},{"key":"17","unstructured":"et al. \"New ASTRO guideline establishes standard of care for curative treatment of oropharyngeal cancer with radiation therapy.\" , (2018)"},{"key":"18","unstructured":"et al. \"Cost of drug development.\" , (2018)"},{"key":"19","unstructured":"DW, Thomas, J, Burns, J, Audette, et al. \"Clinical development success rates 2006\u20132015.\" , (2016)"},{"key":"20","doi-asserted-by":"crossref","unstructured":"L, Rahib, JM, Fleshman, LM, Matrisian, et al. \"JAMA Oncol.\" 2, \"Evaluation of pancreatic cancer clinical trials and benchmarks for clinically meaningful future trials: a systematic review\" 1209 (2016)","DOI":"10.1001\/jamaoncol.2016.0585"},{"key":"21","doi-asserted-by":"crossref","unstructured":"T, Golan, T, Sella, O, Margalit, et al. \"J Natl Compr Canc Netw.\" 15, \"Short- and long-term survival in metastatic pancreatic adenocarcinoma, 1993\u20132013\" 1022 (2017)","DOI":"10.6004\/jnccn.2017.0138"},{"key":"22","doi-asserted-by":"crossref","unstructured":"P, Blumenfeld, RM, Pfeffer, Z, Symon, et al. \"Br J Cancer.\" 111, \"The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?\" 1305 (2014)","DOI":"10.1038\/bjc.2014.448"},{"key":"23","doi-asserted-by":"crossref","unstructured":"KK, Ang, Q, Zhang, DI, Rosenthal, et al. \"J Clin Oncol.\" 32, \"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522\" 2940 (2014)","DOI":"10.1200\/JCO.2013.53.5633"},{"key":"24","doi-asserted-by":"crossref","unstructured":"JD, Bradley, R, Paulus, R, Komaki, et al. \"Lancet Oncol.\" 16, \"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study\" 187 (2015)","DOI":"10.1016\/S1470-2045(14)71207-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"A. Mullard, \"Nat Rev Drug Discov.\" 12, \"Maturing antibody-drug conjugate pipeline hits 30\" 329 (2013)","DOI":"10.1038\/nrd4009"},{"key":"26","doi-asserted-by":"crossref","unstructured":"SR, Adams, HC, Yang, EN, Savariar, et al. \"Nat Commun.\" 7, \"Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize\" 13019 (2016)","DOI":"10.1038\/ncomms13019"},{"key":"27","doi-asserted-by":"crossref","unstructured":"A, Restivo, IMF, Cocco, G, Casula, et al. \"Br J Cancer.\" 113, \"Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer\" 1133 (2015)","DOI":"10.1038\/bjc.2015.336"},{"key":"28","doi-asserted-by":"crossref","unstructured":"HD, Skinner, CH, Crane, CR, Garrett, et al. \"Cancer Med.\" 2, \"Metformin use and improved response to therapy in rectal cancer\" 99 (2013)","DOI":"10.1002\/cam4.54"},{"key":"29","doi-asserted-by":"crossref","unstructured":"N, Aykin-Burns, IM, Ahmad, Y, Zhu, et al. \"Biochem J.\" 418, \"Increased levels of superoxide and hydrogen peroxide mediate the differential susceptibility of cancer cells vs. Normal cells to glucose deprivation\" 29 (2009)","DOI":"10.1042\/BJ20081258"},{"key":"30","doi-asserted-by":"crossref","unstructured":"SN, Rodman, JM, Spence, TJ, Ronnfeldt, et al. \"Radiat Res.\" 186, \"Enhancement of radiation response in breast cancer stem cells by inhibition of thioredoxin- and glutathione-dependent metabolism\" 385 (2016)","DOI":"10.1667\/RR14463.1"},{"key":"31","doi-asserted-by":"crossref","unstructured":"MA, Fath, IM, Ahmad, CJ, Smith, et al. \"Clin Cancer Res.\" 17, \"Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism\" 6206 (2011)","DOI":"10.1158\/1078-0432.CCR-11-0736"},{"key":"32","doi-asserted-by":"crossref","unstructured":"M, Papaioannou, I, Mylonas, RE, Kast, et al. \"Oncoscience.\" 1, \"Disulfiram\/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition\" 21 (2014)","DOI":"10.18632\/oncoscience.5"},{"key":"33","doi-asserted-by":"crossref","unstructured":"M, Diehn, RW, Cho, NA, Lobo, et al. \"Nature.\" 458, \"Association of reactive oxygen species levels and radioresistance in cancer stem cells\" 780 (2009)","DOI":"10.1038\/nature07733"},{"key":"34","doi-asserted-by":"crossref","unstructured":"JD, Schoenfeld, ZA, Sibenaller, KA, Mapuskar, et al. \"Cancer Cell.\" 31, \"O2- and H2O2-mediated disruption of fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate\" 487 (2017)","DOI":"10.1016\/j.ccell.2017.07.008"},{"key":"35","doi-asserted-by":"crossref","unstructured":"J, Du, JA. Cieslak, JL, Welsh, et al. \"Cancer Res.\" 75, \"Pharmacological ascorbate radiosensitizes pancreatic cancer\" 3314 (2015)","DOI":"10.1158\/0008-5472.CAN-14-1707"},{"key":"36","doi-asserted-by":"crossref","unstructured":"JD, Schoenfeld, ZA, Sibenaller, KA, Mapuskar, et al. \"Redox Biol.\" 14, \"Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models\" 417 (2018)","DOI":"10.1016\/j.redox.2017.09.012"},{"key":"37","doi-asserted-by":"crossref","unstructured":"M, Zowczak, M, Iskra, L, Torlinski, et al. \"Biol Trace Elem Res.\" 82, \"Analysis of serum copper and zinc concentrations in cancer patients\" 1 (2001)","DOI":"10.1385\/BTER:82:1-3:001"},{"key":"38","doi-asserted-by":"crossref","unstructured":"A, Gupte and RJ. Mumper \"Cancer Treat Rev.\" 35, \"Elevated copper and oxidative stress in cancer cells as a target for cancer treatment\" 32 (2009)","DOI":"10.1016\/j.ctrv.2008.07.004"},{"key":"39","doi-asserted-by":"crossref","unstructured":"SJ, Sciegienka, SR, Solst, KC, Falls, et al. \"Free Radic Biol Med.\" 108, \"D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress\" 354 (2017)","DOI":"10.1016\/j.freeradbiomed.2017.04.001"},{"key":"40","doi-asserted-by":"crossref","unstructured":"JL, Allensworth, MK, Evans, F, Bertucci, et al. \"Mol Oncol.\" 9, \"Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer\" 1155 (2015)","DOI":"10.1016\/j.molonc.2015.02.007"},{"key":"41","doi-asserted-by":"crossref","unstructured":"A, Gupte and RJ. Mumper \"J Inorg Biochem.\" 101, \"An investigation into copper catalyzed d-penicillamine oxidation and subsequent hydrogen peroxide generation\" 594 (2007)","DOI":"10.1016\/j.jinorgbio.2006.12.007"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Z, Skrott, M, Mistrik, KK, Andersen, et al. \"Nature.\" 552, \"Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4\" 194 (2017)","DOI":"10.1038\/nature25016"},{"key":"43","doi-asserted-by":"crossref","unstructured":"H, Nechushtan, Y, Hamamreh, S, Nidal, et al. \"Oncologist.\" 20, \"A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer\" 366 (2015)","DOI":"10.1634\/theoncologist.2014-0424"},{"key":"44","doi-asserted-by":"crossref","unstructured":"J, Huang, JL, Campian, AD, Gujar, et al. \"J Neurooncol.\" 128, \"A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy\" 259 (2016)","DOI":"10.1007\/s11060-016-2104-2"},{"key":"45","unstructured":"PG, Prasanna, HB, Stone, RS, Wong, et al. \"Transl Cancer Res.\" 1, \"Normal tissue protection for improving radiotherapy: Where are the gaps?\" 35 (2012)"},{"key":"46","doi-asserted-by":"crossref","unstructured":"CG, Begley and LM. Ellis \"Nature.\" 483, \"Drug development: Raise standards for preclinical cancer research\" 531 (2012)","DOI":"10.1038\/483531a"},{"key":"47","doi-asserted-by":"crossref","unstructured":"DE, Citrin, PGS, Prasanna, AJ, Walker, et al. \"Radiat Res.\" 188, \"Radiation-induced fibrosis: mechanisms and opportunities to mitigate. Report of an NCI Workshop, September 19, 2016\" 1 (2017)","DOI":"10.1667\/RR14784.1"},{"key":"48","unstructured":"AS, Morrissy, L, Garzia, DJ, Shih, et al. \"Nature.\" 529, \"Divergent clonal selection dominates medulloblastoma at recurrence\" 351 (2016)"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Y, Jeong, NT, Hoang, A, Lovejoy, et al. \"Cancer Discov.\" 7, \"Role of KEAP1\/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance\" 86 (2017)","DOI":"10.1158\/2159-8290.CD-16-0127"},{"key":"50","doi-asserted-by":"crossref","unstructured":"MM, Ahmed, JW, Hodge, C, Guha, et al. \"Cancer Immunol Res.\" 1, \"Harnessing the potential of radiation-induced immune modulation for cancer therapy\" 280 (2013)","DOI":"10.1158\/2326-6066.CIR-13-0141"},{"key":"51","doi-asserted-by":"crossref","unstructured":"BP, Venkatesulu, S, Mallick, SH, Lin, et al. \"Crit Rev Oncol Hematol.\" 123, \"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors\" 42 (2018)","DOI":"10.1016\/j.critrevonc.2018.01.003"},{"key":"52","unstructured":"et al. \"ClinicalTrials.gov.\" , ()"}],"container-title":["Radiation Research"],"original-title":[],"link":[{"URL":"http:\/\/www.bioone.org\/doi\/full-xml\/10.1667\/RR15121.1","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T05:53:20Z","timestamp":1662184400000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/radiation-research\/volume-190\/issue-4\/RR15121.1\/Radiation-Drug-Combinations-to-Improve-Clinical-Outcomes-and-Reduce-Normal\/10.1667\/RR15121.1.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1667\/rr15121.1","relation":{},"ISSN":["0033-7587"],"issn-type":[{"value":"0033-7587","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}